Topical Treatment of Actinic Keratoses with Piroxicam 1% GelA Preliminary Open-Label Study Utilizing a New Clinical Score

被引：0
|
作者：
Elena Campione
Laura Diluvio
Evelin Jasmine Paternò
Sergio Chimenti
机构：
[1] University of Rome “Tor Vergata”,Department of Dermatology
来源：
American Journal of Clinical Dermatology | 2010年 / 11卷
关键词：
Hyaluronic Acid; Piroxicam; Imiquimod; Actinic Keratose; Etretinate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background: The cyclo-oxygenase enzymes 1 and 2 (COX-1 and COX-2) are both involved in skin tumorigenesis, causing inhibition of apoptosis, angiogenesis, invasiveness, recruitment of growth factors, immunosuppression, and production of carcinogens. Piroxicam is a nonselective nonsteroidal anti-inflammatory drug that blocks the activity of COX-1 and COX-2.
引用
收藏
页码：45 / 50
页数：5
相关论文
共 50 条
  • [1] Topical Treatment of Actinic Keratoses with Piroxicam 1% Gel A Preliminary Open-Label Study Utilizing a New Clinical Score
    Campione, Elena
    Diluvio, Laura
    Paterno, Evelin Jasmine
    Chimenti, Sergio
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2010, 11 (01) : 45 - 50
  • [2] Topical treatment of actinic keratoses with potassium dobesilate 5% cream. A preliminary open-label study
    P Cuevas
    W Espinoza
    C Pérez
    J Angulo
    C Giménez-Gallego
    European Journal of Medical Research, 16
  • [3] TOPICAL TREATMENT OF ACTINIC KERATOSES WITH POTASSIUM DOBESILATE 5% CREAM. A PRELIMINARY OPEN-LABEL STUDY
    Cuevas, P.
    Espinoza, W.
    Perez, C.
    Angulo, J.
    Gimenez-Gallego, G.
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2011, 16 (02) : 67 - 70
  • [4] A phase IV, open-label assessment of the treatment of actinic keratoses with diclofenac sodium 3% topical gel
    Rigel, DS
    Swanson, N
    Wolf, J
    Smith, S
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (03) : P124 - P124
  • [5] A novel topical agent in the treatment of seborrheic keratoses: An open-label pilot study with clinical and dermoscopic evaluation
    Lacarrubba, Francesco
    Nasca, Maria Rita
    Verz, Anna Elisa
    Pulvirenti, Nella
    Micali, Giuseppe
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB19 - AB19
  • [6] Topical 0.5% fluorouracil (FU) cream for the treatment of actinic keratoses (AK): An open-label 18-month safety study
    Stough, D
    Bucko, AD
    Rafal, ES
    Davis, SA
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB176 - AB176
  • [7] An open-label 18-month study of fluorouracil cream 0.5% for the treatment of actinic keratoses
    Stough, Dow
    Davis, Steven A.
    Bucko, Alicia
    Rafal, Elyse
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2008, 58 (02) : AB102 - AB102
  • [8] Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial
    Salasche, SJ
    Levine, N
    Morrison, L
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (04) : 571 - 577
  • [9] Multicenter, open-label study using imiquimod 5% cream in 1 or 2 4-week courses of treatment for multiple actinic keratoses on the head
    Stockfleth, E
    Schmook, T
    Carey-Yard, M
    Bichel, J
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB71 - AB71
  • [10] Fluorouracil Cream 0.5% for Actinic Keratoses on Multiple Body Sites: An 18-Month Open-Label Study
    Stough, Dow
    Bucko, Alicia D.
    Vamvakias, George
    Rafal, Elyse S.
    Davis, Steven A.
    CUTIS, 2010, 85 (05): : 267 - 273
12345